HANSEN-TECHNOLOGIES
17.8.2021 15:02:07 CEST | Business Wire | Press release
Hansen Technologies (ASX:HSN) is pleased to announce today that it has signed a new agreement with wilhelm.tel GmbH, a multi-service provider of telecommunications services in Germany.
Under the terms of this agreement, Hansen will upgrade wilhelm.tel’s existing version of Hansen CCB–NavibillingCX to the latest version and replace their existing CRM system. As a result of this upgrade, wilhelm.tel will receive enhanced customer care, billing and product management capabilities, as well as improved accounting and provisioning processes.
Jens Seedorff, General Manager, wilhelm.tel, commented: “Our partnership with Hansen has a strong track record of operational efficiency. It was based on this that we decided that Hansen were the ideal vendor to help further enable the next chapter of our digital transformation initiative – as we confront not only changing customer expectations, but a telecommunications industry undergoing a major degree of transition as well.”
Scott Weir, Regional President, EMEA, Hansen Technologies, commented : “wilhelm.tel is a longstanding customer of Hansen, supporting their customers for over twenty years with our NavibillingCX product. We are excited to have been selected to not only upgrade wilhelm.tel to our new version of NavibillingCX – based on Microsoft Business Central – but also introduce significant new functionality that improves the customer experience, while accelerating time-to-market. wilhelm.tel’s commitment to Hansen and our product demonstrates the strength of our relationship and provides a strong foundation to future-proof their business for many years to come.”
Hansen CCB , part of the Create-Deliver-Engage Suite of software, provides flexible rating, billing and customer care for communications and pay-TV service providers. Part of the Hansen CCB product family, NavibillingCX is a tailor-made unified solution for fixed and mobile telephony, as well as broadband, IP services, cable TV and interconnect billing. It provides end-to-end customer lifecycle management, and also delivers full ERP capabilities including financial controls, reporting and analytics via Microsoft integration.
For further information about Hansen Technologies, please visit www.hansencx.com .
About Hansen Technologies
Hansen Technologies (ASX: HSN) is a leading global provider of software and services to the energy, water and communications industries. With its award-winning software portfolio, Hansen serves 580+ customers in over 80 countries, helping them to create, sell, and deliver new products and services, manage and analyze customer data, and control critical revenue management and customer support processes.
For more information, visit www.hansencx.com
About wilhelm.tel
Founded in 1999 as a completely owned subsidiary of Stadtwerke Norderstedt, wilhelm.tel GmbH is a nationwide pioneer among operators of high-performance fiber optic networks. From the very beginning, the company has consistently followed a Fiber-to-the-Building strategy, directly connecting every building to its fiber optic network. Since 2020, wilhelm.tel has been increasingly laying fiber optics right up to apartment buildings, thus guaranteeing maximum bandwidth to the customer.
The fiber-optic network, which currently comprises around 2,500 kilometers, has long since crossed the city limits of its home market in Norderstedt and is growing steadily in the direction of Schleswig-Holstein, Hamburg and Lower Saxony. wilhelm.tel regularly sets new standards nationwide with pioneering technology and products and services that are precisely tailored to customer needs. With a resulting market share of up to 90 per cent, wilhelm.tel is considered the most sought-after provider in the Hamburg metropolitan region.
In 2019, wilhelm.tel GmbH, with 130 employees, generated an annual turnover of 73 million euros.
For more information on Wilhelm.tel, visit https://www.wilhelm-tel.de/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210817005190/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom